Brian Lawrence - Feb 27, 2024 Form 4 Insider Report for VAPOTHERM INC (VAPO)

Role
SVP & Chief Technology Officer
Signature
/s/ James Lightman, as Attorney In Fact
Stock symbol
VAPO
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
4
Date filed
2/29/2024, 05:27 PM
Previous filing
Oct 4, 2023
Next filing
Sep 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VAPO Common Stock 60.2K Feb 27, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAPO Stock Option (right to buy) Disposed to Issuer -3.55K -100% 0 Feb 27, 2024 Common Stock 3.55K $165.68 Direct F2, F3
transaction VAPO Stock Option (right to buy) Award +3.55K 3.55K Feb 27, 2024 Common Stock 3.55K $0.92 Direct F2, F3
transaction VAPO Stock Option (right to buy) Disposed to Issuer -6.63K -100% 0 Feb 27, 2024 Common Stock 6.63K $25.28 Direct F3, F4
transaction VAPO Stock Option (right to buy) Award +6.63K 6.63K Feb 27, 2024 Common Stock 6.63K $0.92 Direct F3, F4
transaction VAPO Stock Option (right to buy) Disposed to Issuer -6.83K -100% 0 Feb 27, 2024 Common Stock 6.83K $21.60 Direct F3, F5
transaction VAPO Stock Option (right to buy) Award +6.83K 6.83K Feb 27, 2024 Common Stock 6.83K $0.92 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 37,319 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan.
F2 This option vested as to 25% of the underlying shares on January 1, 2023 and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.
F3 The transactions reported herein reflect a stock option repricing effective February 27, 2024 pursuant to which the exercise price of the repriced options was amended to reduce the exercise price to $0.915 per share, the closing price of the Issuer's common stock on February 27, 2024. There is no change to the expiration dates or the vesting schedule of the repriced options.
F4 This option vested as to 25% of the underlying shares on January 1, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.
F5 This option vested as to 25% of the underlying shares on January 2, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.

Remarks:

On August 18, 2023, a 1-for-8 reverse split of the common stock of Vapotherm, Inc. occurred resulting in a decrease in the number of shares held by the Reporting Person. In addition, proportionate adjustments to the Reporting Person's outstanding equity awards, including the exercise price and number of shares exercisable under the option awards listed in Table II to this Form 4, have been made to reflect the 1-for-8 reverse stock split.